Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13018670 | 0.81 | HRH3 (0.76) | HRH3HRH4ROCK1ROCK2 | |
| SCHEMBL18072491 | 0.80 | HRH3 (0.62) | HRH3HRH4ROCK1ROCK2PTPN11 | |
| SCHEMBL27454974 | 0.80 | HRH3 (0.66) | HRH3HRH4ROCK1ROCK2SORD | |
| SCHEMBL30954035 | 0.80 | HRH3 (0.66) | HRH3HRH4ROCK1ROCK2SORD | |
| SCHEMBL2167882 | 0.79 | HRH3 (1.00) | HRH3HRH4ROCK1 | |
| SCHEMBL2166795 | 0.79 | HRH3 (1.00) | HRH3HRH4ROCK1ROCK2PTPN11 | |
| Hydrochloric Acid SCHEMBL3786113 | 0.78 | HRH3 (0.97) | HRH3HRH4ROCK1ROCK2PTPN11 | |
| Hydrochloric Acid SCHEMBL3781500 | 0.78 | HRH3 (0.97) | HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL26600058 | 0.78 | HRH3 (0.97) | HRH3HRH4 | |
| SCHEMBL17626748 | 0.77 | HRH3 (0.71) | HRH3HRH4ROCK1SORDOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796297-B2 | 4-substituted-2-amino-pyrimidine derivatives | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796297-B2 | 4-substituted-2-amino-pyrimidine derivatives | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100331294-A1 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331294-A1 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331294-A1 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES | HRH2, HRH4, HRH3 | HRH3 3/4885HRH4 2/4885ROCK1 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.